Syngeneic Tumor Models
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Our syngeneic tumor models can be offered as subcutaneous or orthotopic in mice and rats. Mouse-derived tumor cell models involve implantation of commercially available tumor cell lines into mice of the same genetic background to conduct in vivo efficacy evaluation of potential cancer therapies, including targeted therapy, cytotoxic drugs, antibody therapies, and viral therapies.
Standard subcutaneous models are an efficient choice for the determination of the response of tumors to a new drug. Tumor cells are implanted into the flank of mice, and tumor growth is monitored by measuring the volume. Subcutaneous tumor implantation allows for efficient growth of tumors for a variety of analyses such as the impact of drugs on tumor growth, animals survival, and further endpoint analyses such as flow cytometry, expression analysis, histology, and more.
Orthotopic models involve seeding tumor cell lines into the corresponding tissue in animal models. This strategy allows for the assessment of tumor development in a relevant environment and evaluate efficacy in a preclinical tumor model that mimics the disease process in humans. With orthotopic models, we can closely monitor and accurately quantify primary tumor growth, metastatic activity, and response to therapy scenarios.
Examples of mouse syngeneic tumor models that Melior has validated include:
- Breast Cancer – EMT6 Tumor Model
- Fibrosarcoma – WEHI164 Cells
- Lung Cancer – LLC Cells
- Melanoma – B16F10 Syngeneic Mouse Model
Syngeneic Tumor models are most commonly conducted in mice but rats are used as well. A variety of tumorigenic cell lines can be used depending upon the study objectives. In addition to tumor volume a variety of additional physiological parameters and biomarkers, such as cytokine levels, can be incorporated into the study design. Study durations can range from 2 weeks to several months.